BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 37690071)

  • 1. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression.
    Pelkmans W; Shekari M; Brugulat-Serrat A; Sánchez-Benavides G; Minguillón C; Fauria K; Molinuevo JL; Grau-Rivera O; González Escalante A; Kollmorgen G; Carboni M; Ashton NJ; Zetterberg H; Blennow K; Suarez-Calvet M; Gispert JD;
    Alzheimers Dement; 2024 Jan; 20(1):483-493. PubMed ID: 37690071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum.
    Benedet AL; Milà-Alomà M; Vrillon A; Ashton NJ; Pascoal TA; Lussier F; Karikari TK; Hourregue C; Cognat E; Dumurgier J; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Salvadó G; Shekari M; Operto G; Gispert JD; Minguillon C; Fauria K; Kollmorgen G; Suridjan I; Zimmer ER; Zetterberg H; Molinuevo JL; Paquet C; Rosa-Neto P; Blennow K; Suárez-Calvet M;
    JAMA Neurol; 2021 Dec; 78(12):1471-1483. PubMed ID: 34661615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease.
    Ferrari-Souza JP; Ferreira PCL; Bellaver B; Tissot C; Wang YT; Leffa DT; Brum WS; Benedet AL; Ashton NJ; De Bastiani MA; Rocha A; Therriault J; Lussier FZ; Chamoun M; Servaes S; Bezgin G; Kang MS; Stevenson J; Rahmouni N; Pallen V; Poltronetti NM; Klunk WE; Tudorascu DL; Cohen AD; Villemagne VL; Gauthier S; Blennow K; Zetterberg H; Souza DO; Karikari TK; Zimmer ER; Rosa-Neto P; Pascoal TA
    Mol Psychiatry; 2022 Nov; 27(11):4781-4789. PubMed ID: 35948658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The dynamics of plasma biomarkers across the Alzheimer's continuum.
    Guo Y; Shen XN; Wang HF; Chen SD; Zhang YR; Chen SF; Cui M; Cheng W; Dong Q; Ma T; Yu JT
    Alzheimers Res Ther; 2023 Feb; 15(1):31. PubMed ID: 36750875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactive astrogliosis is associated with higher cerebral glucose consumption in the early Alzheimer's continuum.
    Salvadó G; Milà-Alomà M; Shekari M; Ashton NJ; Operto G; Falcon C; Cacciaglia R; Minguillon C; Fauria K; Niñerola-Baizán A; Perissinotti A; Benedet AL; Kollmorgen G; Suridjan I; Wild N; Molinuevo JL; Zetterberg H; Blennow K; Suárez-Calvet M; Gispert JD;
    Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4567-4579. PubMed ID: 35849149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma Glial Fibrillary Acidic Protein Is Associated with 18F-SMBT-1 PET: Two Putative Astrocyte Reactivity Biomarkers for Alzheimer's Disease.
    Chatterjee P; Doré V; Pedrini S; Krishnadas N; Thota R; Bourgeat P; Ikonomovic MD; Rainey-Smith SR; Burnham SC; Fowler C; Taddei K; Mulligan R; Ames D; Masters CL; Fripp J; Rowe CC; Martins RN; Villemagne VL;
    J Alzheimers Dis; 2023; 92(2):615-628. PubMed ID: 36776057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
    Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
    Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathologic and cognitive correlates of plasma biomarkers in neurodegenerative disease.
    Cousins KAQ; Phillips JS; Das SR; O'Brien K; Tropea TF; Chen-Plotkin A; Shaw LM; Nasrallah IM; Mechanic-Hamilton D; McMillan CT; Irwin DJ; Lee EB; Wolk DA
    Alzheimers Dement; 2024 Jun; 20(6):3889-3905. PubMed ID: 38644682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies.
    De Bastiani MA; Bellaver B; Brum WS; Souza DG; Ferreira PCL; Rocha AS; Povala G; Ferrari-Souza JP; Benedet AL; Ashton NJ; Karikari TK; Zetterberg H; Blennow K; Rosa-Neto P; Pascoal TA; Zimmer ER;
    Brain Behav Immun; 2023 May; 110():175-184. PubMed ID: 36878332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Phosphorylated Tau 181 as a Biomarker for Amyloid Burden on Brain PET in Cognitively Healthy Adults.
    McGrath ER; Beiser AS; O'Donnell A; Yang Q; Ghosh S; Gonzales MM; Himali JJ; Satizabal CL; Johnson KA; Tracy RP; Seshadri S
    J Alzheimers Dis; 2022; 87(4):1517-1526. PubMed ID: 35491781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.
    Melah KE; Lu SY; Hoscheidt SM; Alexander AL; Adluru N; Destiche DJ; Carlsson CM; Zetterberg H; Blennow K; Okonkwo OC; Gleason CE; Dowling NM; Bratzke LC; Rowley HA; Sager MA; Asthana S; Johnson SC; Bendlin BB
    J Alzheimers Dis; 2016; 50(3):873-86. PubMed ID: 26836182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers.
    Orduña Dolado A; Stomrud E; Ashton NJ; Nilsson J; Quijano-Rubio C; Jethwa A; Brum WS; Brinkmalm Westman A; Zetterberg H; Blennow K; Janelidze S; Hansson O
    Alzheimers Res Ther; 2024 Jun; 16(1):132. PubMed ID: 38909218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
    Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased cerebrospinal fluid neuronal pentraxin receptor is associated with PET-Aβ load and cerebrospinal fluid Aβ in a pilot study of Alzheimer's disease.
    Lim B; Fowler C; Li QX; Rowe C; Dhiman K; Gupta VB; Masters CL; Doecke JD; Martins RN; Collins S; Diamandis EP
    Neurosci Lett; 2020 Jul; 731():135078. PubMed ID: 32450185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma glial fibrillary acidic protein in autosomal dominant Alzheimer's disease: Associations with Aβ-PET, neurodegeneration, and cognition.
    Chatterjee P; Vermunt L; Gordon BA; Pedrini S; Boonkamp L; Armstrong NJ; Xiong C; Singh AK; Li Y; Sohrabi HR; Taddei K; Molloy M; Benzinger TLS; Morris JC; Karch C; Berman S; Chhatwal J; Cruchaga C; Graff-Radford NR; Day GS; Farlow M; Fox N; Goate A; Hassenstab J; Lee JH; Levin J; McDade E; Mori H; Perrin R; Sanchez-Valle R; Schofield PR; Levey A; Jucker M; Masters CL; Fagan AM; Bateman RJ; Martins RN; Teunissen C;
    Alzheimers Dement; 2023 Jul; 19(7):2790-2804. PubMed ID: 36576155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease.
    Olsen M; Aguilar X; Sehlin D; Fang XT; Antoni G; Erlandsson A; Syvänen S
    Mol Imaging Biol; 2018 Aug; 20(4):605-614. PubMed ID: 29297157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40.
    Deming Y; Black K; Carrell D; Cai Y; Del-Aguila JL; Fernandez MV; Budde J; Ma S; Saef B; Howells B; Bertelsen S; Huang KL; Sutphen CL; Tarawneh R; Fagan AM; Holtzman DM; Morris JC; Goate AM; Dougherty JD; Cruchaga C
    BMC Neurol; 2016 Nov; 16(1):217. PubMed ID: 27832767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
    Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
    Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.
    Craig-Schapiro R; Perrin RJ; Roe CM; Xiong C; Carter D; Cairns NJ; Mintun MA; Peskind ER; Li G; Galasko DR; Clark CM; Quinn JF; D'Angelo G; Malone JP; Townsend RR; Morris JC; Fagan AM; Holtzman DM
    Biol Psychiatry; 2010 Nov; 68(10):903-12. PubMed ID: 21035623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.